Insight Molecular Diagnostics Q2 FY26 net loss widens to $11.26 million; revenue falls to $239,000
Reuters2026/08/10 20:18- Insight Molecular Diagnostics posted Q2 2026 revenue of USD 239,000, down 53.86% from USD 518,000 a year earlier.
- Net loss widened to USD 11.3 million, or USD 0.31 per share, from USD 9.74 million, or USD 0.30 per share.
- Non-GAAP adjusted net loss widened to USD 8.32 million, or USD 0.23 per share, from USD 6.43 million, or USD 0.20 per share.
- Cash, cash equivalents, and restricted cash totaled USD 18.7 million at quarter-end; operating cash outflow was USD 9.27 million.
- FDA completed the current phase of substantive review of GraftAssureDx in late July, requesting additional information as review advances toward expected marketing authorization.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.
Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.
Fogo Foundation Attacked, Approximately 400 Million FOGO Tokens Transferred
Blue Owl (OWL.US) teams up with PIMCO to tailor a $2.4 billion GPU financing for IREN (IREN.US)
A $2.4 billions debt financing round, led by funds under Blue Owl Capital Inc., has been finalized. The funds will be allocated to cloud service provider IREN Ltd. to purchase NVIDIA's Blackwell Ultra GPUs, supporting the development of its data center campus in Canada.
Crypto prices
More
